Novo Nordisk A/S (NVO) Stock Price, News & Analysis

+3.00 (+2.40%)
(As of 01:17 PM ET)
Today's Range
50-Day Range
52-Week Range
2.15 million shs
Average Volume
4.84 million shs
Market Capitalization
$575.57 billion
P/E Ratio
Dividend Yield
Price Target

Novo Nordisk A/S MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
5.3% Upside
$133.60 Price Target
Short Interest
0.06% of Shares Sold Short
Dividend Strength
Based on Four Factors
News Sentiment
0.78mentions of Novo Nordisk A/S in the last 14 days
Based on 28 Articles This Week
Insider Trading
Proj. Earnings Growth
From $3.32 to $4.09 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.05 out of 5 stars

Medical Sector

355th out of 910 stocks

Pharmaceutical Preparations Industry

158th out of 426 stocks

NVO stock logo

About Novo Nordisk A/S Stock (NYSE:NVO)

Novo Nordisk A/S is a global healthcare company specializing in the research, development, production, and marketing of pharmaceutical products to treat diabetes, obesity, and other chronic diseases. The company was founded in 1923 in Denmark and is headquartered in Bagsværd, Denmark.

Novo Nordisk has operations in more than 80 countries, including production facilities in nine countries, and employs approximately 48,500 people worldwide.

Novo Nordisk's mission is to discover and develop innovative medicines to help people with chronic diseases lead longer, healthier lives. The company's key therapeutic areas include diabetes, obesity, hemophilia, growth hormone therapy, and other severe chronic diseases. Novo Nordisk is the world's largest producer of insulin and has been at the forefront of diabetes care for more than 95 years.

Lars Fruergaard Jørgensen is the President and CEO of Novo Nordisk A/S, a position he has held since 2017. Jørgensen joined Novo Nordisk in 1991 and has held various management positions, including Executive Vice President and Head of Corporate Development, Strategy and Biopharmaceuticals.

Novo Nordisk has consistently delivered strong financial performance over the past few years. Novo Nordisk's profit margin has remained consistently high, with a net margin of approximately 30%. In terms of debt, Novo Nordisk has maintained a conservative approach. Novo Nordisk's debt has kept pace with its assets for several years. The company's cash reserves have not always been healthy, but in 2022 Novo Nordisk made a profit for the first time since 2018.

Novo Nordisk's valuation metrics compare favorably to industry peers. It has a price-to-earnings ratio in line with its peers but a price-to-book ratio significantly higher than the industry average. Novo Nordisk's high P/B ratio reflects its strong brand, market position, and financial performance.

Novo Nordisk's stock has performed well over the past few years, with a 3-year annualized return of around 23%. The stock price has shown some volatility, with significant price movements in response to regulatory and market news related to diabetes and obesity markets. 

Novo Nordisk operates in the highly competitive and rapidly evolving pharmaceutical industry, specifically in diabetes and obesity markets. The global diabetes market is expected to grow at a CAGR of 5.7% from 2022 to 2027, driven by the increasing prevalence of diabetes, especially in emerging markets, and the growing demand for innovative diabetes treatments. In the obesity market, the global prevalence of obesity has been steadily increasing, and it is expected to continue to rise, driving demand for effective obesity treatments.

Novo Nordisk faces intense competition from several large and small pharmaceutical companies in the diabetes and obesity markets. The company's main competitors in the diabetes market include Sanofi, Eli Lilly, and AstraZeneca, while its main competitors in the obesity market include Roche, Novartis, and Eisai.

The company's competitive position is based on factors such as the quality and effectiveness of its products, its research and development capabilities, its brand reputation, and ability to adapt to changing market dynamics.

Novo Nordisk is also subject to various regulatory and political issues that can impact its operations and financial performance. The company must comply with strict regulatory requirements in each country it operates, including the US FDA and the European Medicines Agency. Changes in regulatory requirements, such as changes to reimbursement policies, can significantly impact the company's financial performance.

Novo Nordisk has several growth opportunities to pursue in the coming years. The company is investing heavily in research and development to develop new and innovative treatments for diabetes and obesity, as well as other chronic diseases. Novo Nordisk has a strong pipeline of potential products in development, including GLP-1 receptor agonists, which have shown promise in clinical trials for treating obesity.

The company also expands in emerging markets, such as China and India, with significant and growing demand for diabetes and obesity treatments. Novo Nordisk has established partnerships with local companies in these markets to help drive growth and increase product access.

Novo Nordisk has pursued acquisitions and partnerships to expand its product offerings and capabilities. In 2021, the company acquired Prothena's ATTR amyloidosis program, a potential treatment for a rare and debilitating disease. This acquisition will strengthen Novo Nordisk's position in the rare disease market.

Novo Nordisk faces several risks and challenges that could impact its operations and financial performance. The company's success is heavily dependent on the success of its products in the diabetes and obesity markets, and any setbacks in clinical trials or product launches could significantly impact its financial performance.

In addition, Novo Nordisk faces regulatory and political risks, as changes in regulations or policies could impact its ability to operate or sell its products in specific markets. The company is also subject to intellectual property risks, as competitors may seek to challenge its patents and market their products.

Novo Nordisk also faces risks related to supply chain disruptions and production delays, as well as cybersecurity and data privacy risks.

NVO Stock Price History

NVO Stock News Headlines

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
MarketBeat Week in Review – 4/15 - 4/19 (NVO)
The markets continued to move lower ahead of a big earnings week as analysts adjust valuations on the outlook for interest rates and geopolitical concerns
Novo Nordisk Arms Wegovy to Be a Triple Threat
Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide) for obesity.
Novo Nordisk Arms Wegovy to Be a Triple Threat
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? (NVO)
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs? (NVO)
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill (NVO)
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher
DexCom Stock Gains from GLP-1 Diabetic Users (NVO)
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
7 Stocks That Will Drive the Weight Loss Drugs Market (NVO)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Why Novo Nordisk Topped the Market Today
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S (NYSE:NVO) Trading Up 0.5%
3 Biotech Stocks Set to Double by 2028
How to Invest in Novo Nordisk (NVO)
See More Headlines
Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Ex-Dividend for 4/2 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
$12.15 billion
Pretax Margin


Sales & Book Value

Annual Sales
$33.71 billion
Cash Flow
$3.15 per share
Book Value
$3.45 per share


Outstanding Shares
Free Float
Market Cap
$575.66 billion

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Should I Buy Novo Nordisk A/S Stock? NVO Pros and Cons Explained


Here are some ways that investors could benefit from investing in Novo Nordisk:

  • Novo Nordisk A/S has shown consistent growth in revenue and earnings, indicating a strong financial performance.
  • The company has a diverse product portfolio focusing on diabetes, obesity, cardiovascular, and rare diseases, reducing dependency on a single product.
  • Novo Nordisk A/S has a high return on equity of 90.36%, showcasing efficient utilization of shareholder funds.
  • The recent increase in dividend payout to $0.664 per share reflects the company's commitment to rewarding shareholders.
  • With a market cap of $564.80 billion and a steady stock price increase, Novo Nordisk A/S is a stable investment option.


Investors should be bearish about investing in Novo Nordisk for these reasons:

  • Novo Nordisk A/S operates in a highly competitive pharmaceutical industry, facing challenges from new entrants and existing competitors.
  • The company's P/E ratio of 46.49 and PEG ratio of 2.11 suggest that the stock may be overvalued compared to industry peers.
  • Novo Nordisk A/S's debt-to-equity ratio of 0.19 indicates a moderate level of debt, which could impact future financial flexibility.
  • Investors should closely monitor any regulatory changes or legal issues that could affect Novo Nordisk A/S's operations and financial performance.
  • While the stock has shown growth, the beta of 0.41 indicates lower volatility compared to the market, potentially limiting short-term gains.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Novo Nordisk A/S pros and cons to

NVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVO shares.
View NVO analyst ratings
or view top-rated stocks.

What is Novo Nordisk A/S's stock price target for 2024?

8 Wall Street research analysts have issued 1 year price objectives for Novo Nordisk A/S's stock. Their NVO share price targets range from $110.00 to $163.00. On average, they anticipate the company's stock price to reach $133.60 in the next twelve months. This suggests a possible upside of 5.3% from the stock's current price.
View analysts price targets for NVO
or view top-rated stocks among Wall Street analysts.

How have NVO shares performed in 2024?

Novo Nordisk A/S's stock was trading at $103.45 at the beginning of 2024. Since then, NVO stock has increased by 22.6% and is now trading at $126.82.
View the best growth stocks for 2024 here

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,830,000 shares, a decline of 31.1% from the March 15th total of 4,110,000 shares. Based on an average daily volume of 5,070,000 shares, the short-interest ratio is currently 0.6 days.
View Novo Nordisk A/S's Short Interest

When is Novo Nordisk A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NVO earnings forecast

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings data on Wednesday, January, 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a trailing twelve-month return on equity of 90.36%.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a Semi-Annual dividend on Wednesday, January 31st. Shareholders of record on Monday, March 25th will be paid a dividend of $0.664 per share on Tuesday, April 2nd. This represents a yield of 0.9%. The ex-dividend date of this dividend is Friday, March 22nd. This is an increase from the stock's previous Semi-Annual dividend of $0.22.
Read our dividend analysis for NVO

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $1.33 per share and currently has a dividend yield of 1.08%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 49.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 32.52% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

When did Novo Nordisk A/S's stock split?

Shares of Novo Nordisk A/S split before market open on Wednesday, September 20th 2023. The 2-1 split was announced on Wednesday, September 20th 2023. The newly minted shares were payable to shareholders after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S issued an update on its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $39.2 billion-$41.9 billion, compared to the consensus revenue estimate of $40.2 billion.

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Folketrygdfondet (0.20%), Everett Harris & Co. CA (0.14%), Raymond James & Associates (0.07%), Saratoga Research & Investment Management (0.02%), Norden Group LLC (0.01%) and Sapient Capital LLC (0.01%).
View institutional ownership trends

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novo Nordisk A/S have any subsidiaries?
The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia Therapeutics, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
This page (NYSE:NVO) was last updated on 4/23/2024 by Staff

From Our Partners